Patents Assigned to Elixir Pharmaceuticals, Inc.
-
Publication number: 20160113903Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.Type: ApplicationFiled: June 4, 2015Publication date: April 28, 2016Applicant: ELIXIR PHARMACEUTICALS, INC.Inventors: Andrew D. Napper, Peter DiStefano, Rory Curtis, Jeffrey Hixon, Thomas E. McDonagh, L. Julie Huber, Jonathan M. Solomon, Russel J. Thomas, Jean-francois Pons
-
Publication number: 20140163029Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.Type: ApplicationFiled: May 24, 2013Publication date: June 12, 2014Applicant: ELIXIR PHARMACEUTICALS, INC.Inventors: Andrew D. Napper, Peter DiStefano, Rory Curtis, Jeffrey Hixon, Thomas E. McDonagh, L. Julie Huber, Jonathan M. Solomon, Russel J. Thomas, Jean-francois Pons
-
Patent number: 8486990Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.Type: GrantFiled: April 14, 2009Date of Patent: July 16, 2013Assignee: Elixir Pharmaceuticals, Inc.Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
-
Patent number: 7897765Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.Type: GrantFiled: February 9, 2009Date of Patent: March 1, 2011Assignee: Elixir Pharmaceuticals, Inc.Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
-
Patent number: 7829589Abstract: Compounds that modulate GHS-R are described, for examples compounds formula (I)Type: GrantFiled: November 29, 2006Date of Patent: November 9, 2010Assignee: Elixir Pharmaceuticals, Inc.Inventors: Jeffrey O. Saunders, Thomas Coulter, Paul Mortenson, Manuel A. Navia, Jean-Francois Pons
-
Patent number: 7771961Abstract: Modulation of cytochrome c acetylation, e.g., with a SIR polypeptide, enables interventions that modulate lifespan regulation and cell proliferation, e.g., by modulating apoptosis and/or mitochondrial function such as respiration.Type: GrantFiled: July 10, 2009Date of Patent: August 10, 2010Assignee: Elixir Pharmaceuticals, IncInventors: L. Julie Huber, Jonathan M. Solomon
-
Publication number: 20090306168Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.Type: ApplicationFiled: April 14, 2009Publication date: December 10, 2009Applicant: ELIXIR PHARMACEUTICALS, INC.Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
-
Publication number: 20090264410Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.Type: ApplicationFiled: February 9, 2009Publication date: October 22, 2009Applicant: ELIXIR PHARMACEUTICALS, INC.Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
-
Patent number: 7575883Abstract: Modulation of cytochrome c acetylation, e.g., with a SIR polypeptide, enables interventions that modulate lifespan regulation and cell proliferation, e.g., by modulating apoptosis and/or mitochondrial function such as respiration.Type: GrantFiled: December 15, 2003Date of Patent: August 18, 2009Assignee: Elixir Pharmaceuticals, Inc.Inventors: L. Julie Huber, Jonathan M. Solomon
-
Patent number: 7504506Abstract: Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.Type: GrantFiled: November 4, 2004Date of Patent: March 17, 2009Assignee: Elixir Pharmaceuticals, Inc.Inventors: Peter Distefano, Andrew Napper, Rory Curtis, Jay Luly, Manuel A. Navia, Russell J. Thomas, Jean-Francois Pons, Jeffrey O. Saunders
-
Publication number: 20080261970Abstract: Compounds of formula (I), including methods of making and methods of using are described in formula (I).Type: ApplicationFiled: September 27, 2005Publication date: October 23, 2008Applicant: ELIXIR PHARMACEUTICALS, INC.Inventors: Jeffrey O. Saunders, Andrew D. Napper
-
Publication number: 20080261873Abstract: Disclosed are methods of treating a disorder of the stomach, intestine or duodenum in a human subject. The method includes administering to the subject, a pharmaceutical composition comprising a compound that increases gastrointestinal motility (e.g., by modulating myenteric nerve activity) and/or induces the secretion or production of growth hormone.Type: ApplicationFiled: August 18, 2005Publication date: October 23, 2008Applicant: ELIXIR PHARMACEUTICALS, INC.Inventor: Bard J. Geesaman
-
Publication number: 20040175700Abstract: Information for each individual of a first group of individuals and each individual of a second group of individuals is used to select a subset of individuals from the second group. The information can be about a plurality of different biological features. The selection can use a comparison between information for members of the first group and information for members of the subset. It is also possible to compare members of the first group to members of the selected subset with respect to at least one factor. The method can be used to reduce stratification, for example, in the analysis of genetic associations.Type: ApplicationFiled: March 3, 2003Publication date: September 9, 2004Applicant: ELIXIR PHARMACEUTICALS, INC.Inventor: Bard J. Geesaman
-
Publication number: 20040121407Abstract: This disclosure provides, inter alia, treatments and compositions that alter life span regulation and cellular responses to diseases and disorders by antagonizing the GH/IGF-1 axis. Also provided are methods of screening for agents that can modulate the GH/IGF-1 axis.Type: ApplicationFiled: September 5, 2003Publication date: June 24, 2004Applicant: ELIXIR PHARMACEUTICALS, INC.Inventors: Peter Distefano, Cynthia A. Bayley, L. Edward Cannon